Sorted By:

Relevance


ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Allow a full range of truthful and non-misleading communications between innovators and payers for all medically accepted uses of medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

Medicare Monday: Catch up on MedPAC and its Part B recommendations

PhRMA  |  Blog Post

For policy wonks, you can get up to speed with our Memorial Day reading list on the Medicare Payment Advisory Commission (MedPAC), how it informs Medicare policy and its recent Part B recommendations, which are expected to be included in their report to Congress this June.
http://catalyst.phrma.org/medicare-monday-catch-up-on-medpac-and-its-part-b-recommendations

How do multiple sclerosis patients define value?

PhRMA  |  Blog Post

While this information is useful to payers, it fails to acknowledge the costs that matter to patients.
http://catalyst.phrma.org/how-do-multiple-sclerosis-patients-define-value

Medicare Monday: Billing code basics for biologics in Part B

PhRMA  |  Blog Post

We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before.
http://catalyst.phrma.org/medicare-monday-billing-code-basics-biologics-part-b

Cells - Leukemia and Lymphoma

PhRMA  |  Video

America’s biopharmaceutical companies are working to harness the power of the body’s immune system to fight infectious diseases and cancers like leukemia and lymphoma. 
https://www.phrma.org

Fact Check Friday: The truth about IPAB

PhRMA  |  Blog Post

IPAB, as designed, grants largely unchecked power to the board or Secretary of HHS to make widespread changes to Medicare without congressional approval.
http://catalyst.phrma.org/fact-check-friday-the-truth-about-ipab

Value Collaborative Videos

PhRMA  |  From PhRMA

Public Policy, GlaxoSmithKline Patricia J.
https://www.phrma.org/media/value-collaborative-videos

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

PhRMA  |  Blog Post

Read the full white paper summarizing these recommendations here.
http://catalyst.phrma.org/icymi-multi-stakeholder-group-recommended-changes-to-support-value-driven-health-care

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Allow a full range of truthful and non-misleading communications between innovators and payers for all medically accepted uses of medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Allow a full range of truthful and non-misleading communications between innovators and payers for all medically accepted uses of medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

Opening the conversation around mental health treatment with advocates & industry leaders

PhRMA  |  Blog Post

As an outspoken mental health advocate, Chamique Holdsclaw shared her own struggles with mental health and reflected on the power of transparency to change perceptions.
http://catalyst.phrma.org/opening-the-conversation-around-mental-health-treatment-with-advocates-industry-leaders

Senior Director – Federal Advocacy

PhRMA  |  PhRMA Career

Requirements Bachelor’s degree in Political Science, Government Relations, Public Policy, or other related field of study;  5-7 years of direct experience working with or for the Congress and/or Federal Advocacy work; Understanding of procedures, protocols of standing committees regarding witnesses, testimony and Congressional activities, working knowledge of the Congressional process and ethics rules and regulations; Strong relationship building skills, integrity and reputation; easily builds a rapport and can persuade others Strategically anticipates potential future federal advocacy issues; Strong verbal and written communication skills; Demonstrated collaborator and team player.
https://www.phrma.org/careers/senior-director-federal-advocacy

VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY

PhRMA  |  Blog Post

The campaign heralds the new era of medicine and will convene a national dialogue on policy solutions to sustain bold advancements.
http://catalyst.phrma.org/video-phrma-ceo-joins-cnbcs-squawk-on-the-street-to-discuss-new-industry-campaign-go-boldly

340B Spotlight: Audit findings show importance of increased oversight of 340B program

PhRMA  |  Blog Post

The paper also predicts that exponential growth will continue for at least the next five years.
http://catalyst.phrma.org/340b-spotlight-audit-findings-show-importance-of-increased-oversight-of-340b-program

Director - Advocacy and Strategic Alliance

PhRMA  |  PhRMA Career

Professional Experience / Requirements Bachelor’s degree in Political Science, Public Policy, Public Health or related field (Master’s degree related discipline preferred; 5+ years of experience working in the patient advocacy community, the Federal government, or with Congress; Sophisticated policy analysis skills; Experience in coalition-building; Strong understanding of FDA regulatory, drug development and approval processes; Understanding of public health programs, including Medicare, Medicaid, and the Affordable Care Act; Understanding of the legislative process; Ability to inspire confidence within the organization and with external constituencies; Must be willing to travel and be both responsive and available after hours and on weekends.
https://www.phrma.org/careers/director-advocacy-and-strategic-alliance

Berkeley Research Group Study on the Pharmaceutical Supply Chain

PhRMA  |  Report

By using this starting point, the analysis makes it possible to measure prescription drug spending by consumers, health plans, government payers, and employers, and the portion thereof realized by manufacturer and non-manufacturer stakeholders.
https://www.phrma.org/report/berkeley-research-group-study-on-the-pharmaceutical-supply-chain

Highlights from Tackling Diabetes: Solutions to a Complex Disease

PhRMA  |  Video

The discussion, led by The Hill’s National Correspondent Reid Wilson and Health Care Reporter Sarah Ferris, addressed how to stop the spread of this disease through policy initiatives and regulatory reforms and explore how the current landscape of diabetes care could be changed by a potential repeal of the Affordable Care Act.
https://www.phrma.org/video/highlights-from-tackling-diabetes-solutions-to-a-complex-disease

Point of Sale Rebate Analysis in the Commercial Market

PhRMA  |  Report

This report by Milliman observes the reallocation in payer costs and member cost sharing relative to a baseline scenario across varying plan designs typically found in the employer market.
https://www.phrma.org/report/point-of-sale-rebate-analysis-in-the-commercial-market

Las Compañías Biofarmacéuticas de Estados Unidos Lanzan una Innovadora Iniciativa Anunciando la Nueva Era de la Medicina

PhRMA  |  Press Release

"También vamos a convocar eventos con los interesados en todo el país para discutir formas en que podemos trabajar juntos para hacer que nuestro sistema de atención de la salud responda mejor a las necesidades de los pacientes."
https://www.phrma.org/press-release/las-compa-as-biofarmac-uticas-de-estados-unidos-lanzan-una-innovadora-iniciativa-anunciando-la-nueva-era-de-la-medicina

The Value of Innovation in Oncology

PhRMA  |  Report

A new white paper by Boston Healthcare Associates examines how innovative medicines are driving significant progress in the fight against cancer.
https://www.phrma.org/report/the-value-of-innovation-in-oncology

340B Spotlight: Trends in shifting site of care

PhRMA  |  Blog Post

Learn more about policy solutions to address market distortions here
http://catalyst.phrma.org/340b-spotlight-trends-in-shifting-site-of-care

Patient voices missing from media conversation about prescription drug abuse

PhRMA  |  Blog Post

PhRMA strongly supports these efforts as part of our extensive policy recommendations to combat opioid abuse, which you can find explained in-depth here.
http://catalyst.phrma.org/patient-voices-missing-from-media-conversation-about-prescription-drug-abuse

Manager – Public Affairs

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.
https://www.phrma.org

Medicare Monday: What the experts are saying about the Independent Payment Advisory Board

PhRMA  |  Blog Post

The Independent Payment Advisory Board (IPAB), a panel of 15 members selected by the President and confirmed by the Senate, is tasked with proposing cuts to Medicare if spending exceeds a certain growth target. 
http://catalyst.phrma.org/medicare-monday-what-the-experts-are-saying-about-the-independent-payment-advisory-board

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

PhRMA  |  Blog Post

Leonard Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society “As far as I’m concerned, this paper sets a lower bound, and that’s all.” – Derek Lowe, Ph.D., Science Translational Medicine  
http://catalyst.phrma.org/what-they-are-saying-study-on-cancer-rd-costs-is-not-an-accurate-representation-of-marketplace

You have reviewed the first 150 results out of 1100. Each page contains 25 results. You're on page 6.

prev 1 2 3 4 5 6 next